Institute of Pharmaceutics, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, China; Hangzhou Institute of Innovative Medicine, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, China.
Institute of Pharmaceutics, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, China.
Int J Pharm. 2022 May 25;620:121757. doi: 10.1016/j.ijpharm.2022.121757. Epub 2022 Apr 18.
Pulmonary diseases are currently one of the major threats of human health, especially considering the recent COVID-19 pandemic. However, the current treatments are facing the challenges like insufficient local drug concentrations, the fast lung clearance and risks to induce unexpected inflammation. Cell-derived membrane biomimetic nanocarriers are recently emerged delivery strategy, showing advantages of long circulation time, excellent biocompatibility and immune escape ability. In this review, applications of using cell-derived membrane biomimetic nanocarriers from diverse cell sources for the targeted therapy of pulmonary disease were summarized. In addition, improvements of the cell-derived membrane biomimetic nanocarriers for augmented therapeutic ability against different kinds of pulmonary diseases were introduced. This review is expected to provide a general guideline for the potential applications of cell-derived membrane biomimetic nanocarriers to treat pulmonary diseases.
肺部疾病是目前威胁人类健康的主要因素之一，尤其是在最近的 COVID-19 大流行期间。然而，目前的治疗方法面临着局部药物浓度不足、肺部快速清除以及引发意外炎症的风险等挑战。细胞衍生的膜仿生纳米载体是一种新兴的递药策略，具有长循环时间、良好的生物相容性和免疫逃逸能力等优点。本综述总结了不同细胞来源的细胞衍生膜仿生纳米载体在肺部疾病靶向治疗中的应用。此外，还介绍了为增强针对不同类型肺部疾病的治疗能力而对细胞衍生膜仿生纳米载体进行的改进。本综述有望为细胞衍生膜仿生纳米载体在治疗肺部疾病方面的潜在应用提供一个总体指导。
